Patents by Inventor Douglas Sutton

Douglas Sutton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170232275
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: October 3, 2016
    Publication date: August 17, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 9731132
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: August 15, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark Deem, Denise Zarins, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Publication number: 20170215949
    Abstract: Described here are methods and systems for the manipulation of ovarian tissues. The methods and systems may be used in the treatment of polycystic ovary syndrome (PCOS). The systems and methods may be useful in the treatment of infertility associated with PCOS.
    Type: Application
    Filed: April 21, 2017
    Publication date: August 3, 2017
    Inventors: Denise ZARINS, Neil BARMAN, Garrett SCHWAB, Roger OSBORNE, Douglas SUTTON
  • Patent number: 9675413
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: June 13, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark E. Deem, Hanson Gifford, III, Denise Zarins, Douglas Sutton, Erik Thai, Mark Gelfand, Howard R. Levin
  • Patent number: 9636174
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: March 3, 2016
    Date of Patent: May 2, 2017
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20170106239
    Abstract: A method and system for tracking physical metrics in an electronic networking system is disclosed. According to one embodiment, the physical metric tracking system comprises a data registering unit that receives activity data by a user, a data processing unit that validates the activity data using a plurality of data validating algorithms and converts the validated data into a convertible value, and a storage that stores the activity data and the convertible value. The convertible value is traded with goods and services, or any other benefits in the social commerce system.
    Type: Application
    Filed: December 22, 2016
    Publication date: April 20, 2017
    Inventors: Rick Douglas Sutton, Joseph Whitney Fabris
  • Publication number: 20170080230
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: September 1, 2016
    Publication date: March 23, 2017
    Inventors: Mark Deem, Denise Zarins, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Publication number: 20170080214
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: September 19, 2016
    Publication date: March 23, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20170065336
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: March 17, 2016
    Publication date: March 9, 2017
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20170056242
    Abstract: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.
    Type: Application
    Filed: August 5, 2016
    Publication date: March 2, 2017
    Inventors: Yair Alster, Eugene de Juan, JR., Cary J. Reich, Stephen Boyd, David Sierra, Jose D. Alejandro, K. Angela Macfarlane, Douglas Sutton
  • Publication number: 20170023800
    Abstract: A conformable covering comprises an outer portion with rigidity to resist movement on the cornea and an inner portion to contact the cornea and provide an environment for epithelial regeneration. The inner portion of the covering can be configured in many ways so as to conform at least partially to an ablated stromal surface so as to correct vision. The conformable inner portion may have at least some rigidity so as to smooth the epithelium such that the epithelium regenerates rapidly and is guided with the covering so as to form a smooth layer for vision. The inner portion may comprise an amount of rigidity within a range from about 1×10?4 Pa*m3 to about 5×10?4 Pa*m3 so as to deflect and conform at least partially to the ablated cornea and smooth an inner portion of the ablation with an amount of pressure when deflected.
    Type: Application
    Filed: October 10, 2016
    Publication date: January 26, 2017
    Inventors: Eugene de Juan, JR., Cary J. Reich, Yair Alster, K. Angela Macfarlane, Doug Rimer, Douglas Sutton, Dean Carson, Enrique Barragan, Matt Clarke, Ashley Tuan, Brian Levy
  • Patent number: 9498385
    Abstract: A conformable covering comprises an outer portion with rigidity to resist movement on the cornea and an inner portion to contact the cornea and provide an environment for epithelial regeneration. The inner portion of the covering can be configured in many ways so as to conform at least partially to an ablated stromal surface so as to correct vision. The conformable inner portion may have at least some rigidity so as to smooth the epithelium such that the epithelium regenerates rapidly and is guided with the covering so as to form a smooth layer for vision. The inner portion may comprise an amount of rigidity within a range from about 1×10?4 Pa*m3 to about 5×10?4 Pa*m3 so as to deflect and conform at least partially to the ablated cornea and smooth an inner portion of the ablation with an amount of pressure when deflected.
    Type: Grant
    Filed: October 25, 2010
    Date of Patent: November 22, 2016
    Assignee: NexisVision, Inc.
    Inventors: Eugene de Juan, Jr., Cary J. Reich, Yair Alster, K. Angela MacFarlane, Doug Rimer, Douglas Sutton, Dean Carson, Enrique Barragan, Matt Clarke, Ashley Tuan, Brian Levy
  • Patent number: 9486270
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: August 3, 2015
    Date of Patent: November 8, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 9474563
    Abstract: Methods and apparatus are provided for treating contrast nephropathy, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: October 25, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20160296279
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for percutaneous intravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Application
    Filed: April 28, 2016
    Publication date: October 13, 2016
    Applicant: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark E. DEEM, Hanson GIFFORD, III, Denise ZARINS, Douglas SUTTON, Erik THAI, Mark GELFAND, Howard R. LEVIN
  • Patent number: 9463066
    Abstract: Methods and apparatus are provided for renal neuromodulation using a pulsed electric field to effectuate electroporation or electrofusion. It is expected that renal neuromodulation (e.g., denervation) may, among other things, reduce expansion of an acute myocardial infarction, reduce or prevent the onset of morphological changes that are affiliated with congestive heart failure, and/or be efficacious in the treatment of end stage renal disease. Embodiments of the present invention are configured for extravascular delivery of pulsed electric fields to achieve such neuromodulation.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: October 11, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Mark Deem, Denise Zarins, Douglas Sutton, Hanson Gifford, III, Howard R. Levin, Mark Gelfand, Benjamin J. Clark
  • Patent number: 9456869
    Abstract: Methods and apparatus are provided for bilateral renal neuromodulation, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: October 4, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 9439726
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Grant
    Filed: March 14, 2016
    Date of Patent: September 13, 2016
    Assignee: Medtronic Ardian Luxembourg S.a.r.l.
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Publication number: 20160250460
    Abstract: Methods and apparatus are provided for treating hypertension, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
    Type: Application
    Filed: March 3, 2016
    Publication date: September 1, 2016
    Inventors: Denise Zarins, Hanson Gifford, III, Mark Deem, Douglas Sutton, Howard R. Levin, Mark Gelfand
  • Patent number: 9421126
    Abstract: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: August 23, 2016
    Assignee: ForSight Vision5, Inc.
    Inventors: Yair Alster, Eugene de Juan, Jr., Cary J. Reich, Stephen Boyd, David Sierra, Jose D. Alejandro, K. Angela Macfarlane, Douglas Sutton